Graham Capital Management L.P. Has $1.16 Million Holdings in Neumora Therapeutics, Inc. $NMRA

Graham Capital Management L.P. lifted its stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 1,643.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,162,499 shares of the company’s stock after buying an additional 1,095,830 shares during the period. Graham Capital Management L.P. owned about 0.72% of Neumora Therapeutics worth $1,162,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Lunate Capital Ltd acquired a new stake in Neumora Therapeutics in the first quarter valued at $2,124,000. Northern Trust Corp lifted its holdings in Neumora Therapeutics by 7.7% during the 4th quarter. Northern Trust Corp now owns 734,847 shares of the company’s stock worth $7,789,000 after buying an additional 52,464 shares during the period. Stempoint Capital LP acquired a new position in Neumora Therapeutics during the 4th quarter worth about $4,538,000. Cerity Partners LLC lifted its holdings in Neumora Therapeutics by 24.0% during the 1st quarter. Cerity Partners LLC now owns 302,505 shares of the company’s stock worth $303,000 after buying an additional 58,597 shares during the period. Finally, Federated Hermes Inc. acquired a new position in Neumora Therapeutics during the 1st quarter worth about $285,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Neumora Therapeutics Stock Performance

NMRA stock opened at $1.75 on Thursday. The stock has a 50-day moving average price of $1.53 and a 200-day moving average price of $1.16. Neumora Therapeutics, Inc. has a 1-year low of $0.61 and a 1-year high of $17.19. The company has a current ratio of 10.54, a quick ratio of 10.54 and a debt-to-equity ratio of 0.11. The firm has a market cap of $283.41 million, a PE ratio of -1.11 and a beta of 2.91.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.05. As a group, equities research analysts expect that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 target price on shares of Neumora Therapeutics in a report on Tuesday, May 13th. Mizuho lifted their target price on Neumora Therapeutics from $4.00 to $5.00 and gave the stock an “outperform” rating in a report on Wednesday, July 16th. Three analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Neumora Therapeutics presently has an average rating of “Hold” and a consensus target price of $7.14.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.